hampshire oncology limited
hampshire oncology limited Company Information
Company Number
09860666
Next Accounts
Dec 2025
Shareholders
catherine mary heath
giles matthew hudson
Group Structure
View All
Industry
General medical practice activities
Registered Address
badger house salisbury road, blandford forum, DT11 7QD
Website
www.nhoh.comhampshire oncology limited Estimated Valuation
Pomanda estimates the enterprise value of HAMPSHIRE ONCOLOGY LIMITED at £468.3k based on a Turnover of £1.1m and 0.41x industry multiple (adjusted for size and gross margin).
hampshire oncology limited Estimated Valuation
Pomanda estimates the enterprise value of HAMPSHIRE ONCOLOGY LIMITED at £415k based on an EBITDA of £135.6k and a 3.06x industry multiple (adjusted for size and gross margin).
hampshire oncology limited Estimated Valuation
Pomanda estimates the enterprise value of HAMPSHIRE ONCOLOGY LIMITED at £1.1m based on Net Assets of £430.8k and 2.51x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Hampshire Oncology Limited Overview
Hampshire Oncology Limited is a live company located in blandford forum, DT11 7QD with a Companies House number of 09860666. It operates in the general medical practice activities sector, SIC Code 86210. Founded in November 2015, it's largest shareholder is catherine mary heath with a 75% stake. Hampshire Oncology Limited is a established, small sized company, Pomanda has estimated its turnover at £1.1m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Hampshire Oncology Limited Health Check
Pomanda's financial health check has awarded Hampshire Oncology Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
5 Weak
Size
annual sales of £1.1m, make it smaller than the average company (£2m)
- Hampshire Oncology Limited
£2m - Industry AVG
Growth
3 year (CAGR) sales growth of 32%, show it is growing at a faster rate (10.5%)
- Hampshire Oncology Limited
10.5% - Industry AVG
Production
with a gross margin of 20.4%, this company has a higher cost of product (39.5%)
- Hampshire Oncology Limited
39.5% - Industry AVG
Profitability
an operating margin of 11.9% make it more profitable than the average company (3.7%)
- Hampshire Oncology Limited
3.7% - Industry AVG
Employees
with 2 employees, this is below the industry average (23)
2 - Hampshire Oncology Limited
23 - Industry AVG
Pay Structure
on an average salary of £34.6k, the company has an equivalent pay structure (£34.6k)
- Hampshire Oncology Limited
£34.6k - Industry AVG
Efficiency
resulting in sales per employee of £567.6k, this is more efficient (£87.3k)
- Hampshire Oncology Limited
£87.3k - Industry AVG
Debtor Days
it gets paid by customers after 149 days, this is later than average (30 days)
- Hampshire Oncology Limited
30 days - Industry AVG
Creditor Days
its suppliers are paid after 13 days, this is quicker than average (25 days)
- Hampshire Oncology Limited
25 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Hampshire Oncology Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Hampshire Oncology Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 7.5%, this is a lower level of debt than the average (56.3%)
7.5% - Hampshire Oncology Limited
56.3% - Industry AVG
HAMPSHIRE ONCOLOGY LIMITED financials
Hampshire Oncology Limited's latest turnover from March 2024 is estimated at £1.1 million and the company has net assets of £430.8 thousand. According to their latest financial statements, Hampshire Oncology Limited has 2 employees and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | ||||||||
| Other Income Or Grants | ||||||||
| Cost Of Sales | ||||||||
| Gross Profit | ||||||||
| Admin Expenses | ||||||||
| Operating Profit | ||||||||
| Interest Payable | ||||||||
| Interest Receivable | ||||||||
| Pre-Tax Profit | ||||||||
| Tax | ||||||||
| Profit After Tax | ||||||||
| Dividends Paid | ||||||||
| Retained Profit | ||||||||
| Employee Costs | ||||||||
| Number Of Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 394 | 525 | 700 | 934 | 1,245 | 661 | 114 | 152 |
| Intangible Assets | ||||||||
| Investments & Other | ||||||||
| Debtors (Due After 1 year) | ||||||||
| Total Fixed Assets | 394 | 525 | 700 | 934 | 1,245 | 661 | 114 | 152 |
| Stock & work in progress | ||||||||
| Trade Debtors | 465,562 | 352,395 | 262,163 | 226,893 | 158,484 | 129,686 | 63,428 | 42,283 |
| Group Debtors | ||||||||
| Misc Debtors | ||||||||
| Cash | ||||||||
| misc current assets | ||||||||
| total current assets | 465,562 | 352,395 | 262,163 | 226,893 | 158,484 | 129,686 | 63,428 | 42,283 |
| total assets | 465,956 | 352,920 | 262,863 | 227,827 | 159,729 | 130,347 | 63,542 | 42,435 |
| Bank overdraft | ||||||||
| Bank loan | ||||||||
| Trade Creditors | 33,366 | 22,235 | 11,567 | 15,820 | 9,702 | 15,408 | 6,659 | 11,571 |
| Group/Directors Accounts | ||||||||
| other short term finances | ||||||||
| hp & lease commitments | ||||||||
| other current liabilities | ||||||||
| total current liabilities | 33,366 | 22,235 | 11,567 | 15,820 | 9,702 | 15,408 | 6,659 | 11,571 |
| loans | ||||||||
| hp & lease commitments | ||||||||
| Accruals and Deferred Income | 1,752 | 1,518 | 1,510 | 1,347 | 1,284 | 1,260 | 1,080 | 960 |
| other liabilities | ||||||||
| provisions | ||||||||
| total long term liabilities | 1,752 | 1,518 | 1,510 | 1,347 | 1,284 | 1,260 | 1,080 | 960 |
| total liabilities | 35,118 | 23,753 | 13,077 | 17,167 | 10,986 | 16,668 | 7,739 | 12,531 |
| net assets | 430,838 | 329,167 | 249,786 | 210,660 | 148,743 | 113,679 | 55,803 | 29,904 |
| total shareholders funds | 430,838 | 329,167 | 249,786 | 210,660 | 148,743 | 113,679 | 55,803 | 29,904 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | ||||||||
| Depreciation | ||||||||
| Amortisation | ||||||||
| Tax | ||||||||
| Stock | ||||||||
| Debtors | 113,167 | 90,232 | 35,270 | 68,409 | 28,798 | 66,258 | 21,145 | 42,283 |
| Creditors | 11,131 | 10,668 | -4,253 | 6,118 | -5,706 | 8,749 | -4,912 | 11,571 |
| Accruals and Deferred Income | 234 | 8 | 163 | 63 | 24 | 180 | 120 | 960 |
| Deferred Taxes & Provisions | ||||||||
| Cash flow from operations | ||||||||
| Investing Activities | ||||||||
| capital expenditure | ||||||||
| Change in Investments | ||||||||
| cash flow from investments | ||||||||
| Financing Activities | ||||||||
| Bank loans | ||||||||
| Group/Directors Accounts | ||||||||
| Other Short Term Loans | ||||||||
| Long term loans | ||||||||
| Hire Purchase and Lease Commitments | ||||||||
| other long term liabilities | ||||||||
| share issue | ||||||||
| interest | ||||||||
| cash flow from financing | ||||||||
| cash and cash equivalents | ||||||||
| cash | ||||||||
| overdraft | ||||||||
| change in cash |
hampshire oncology limited Credit Report and Business Information
Hampshire Oncology Limited Competitor Analysis
Perform a competitor analysis for hampshire oncology limited by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in DT11 area or any other competitors across 12 key performance metrics.
hampshire oncology limited Ownership
HAMPSHIRE ONCOLOGY LIMITED group structure
Hampshire Oncology Limited has no subsidiary companies.
Ultimate parent company
HAMPSHIRE ONCOLOGY LIMITED
09860666
hampshire oncology limited directors
Hampshire Oncology Limited currently has 2 directors. The longest serving directors include Dr Catherine Heath (Nov 2015) and Mr Giles Hudson (Nov 2015).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Dr Catherine Heath | United Kingdom | 56 years | Nov 2015 | - | Director |
| Mr Giles Hudson | 53 years | Nov 2015 | - | Director |
P&L
March 2024turnover
1.1m
+59%
operating profit
135.6k
0%
gross margin
20.4%
-1.49%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
430.8k
+0.31%
total assets
466k
+0.32%
cash
0
0%
net assets
Total assets minus all liabilities
hampshire oncology limited company details
company number
09860666
Type
Private limited with Share Capital
industry
86210 - General medical practice activities
incorporation date
November 2015
age
10
incorporated
UK
ultimate parent company
accounts
Micro-Entity Accounts
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
-
address
badger house salisbury road, blandford forum, DT11 7QD
Bank
-
Legal Advisor
-
hampshire oncology limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to hampshire oncology limited.
hampshire oncology limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for HAMPSHIRE ONCOLOGY LIMITED. This can take several minutes, an email will notify you when this has completed.
hampshire oncology limited Companies House Filings - See Documents
| date | description | view/download |
|---|
